The Centre for Global Vaccine Research
Working to develop and implement the use of vaccines against major infectious diseases.
Developing and trialing, in phase 1 studies, a vaccine to prevent zika infection. Based on a heterologous prime boost with different pox virus vectors to induce durable B and T cell responses against multiple viral antigens with a focus on use in pregnant women.
AMR in Streptococcus pneumoniae is spread globally by a limited number of clones. PCV vaccination has decresed AMR among vaccine-type strains. AMR now emerges by expansion of non-PCV types. The project focuses on genetic/functional properties of AMR clones with the goal to target their success and transmission in the carrier population.
The study aims to investigate the different factors that can affect how effective rotavirus vaccine is in different children. In this study, the protection passed on from mothers to babies during pregnancy and after birth will be compared across Liverpool, India and Malawi. Additionally, the bacteria in the baby's stool from birth to the time of rotavirus vaccination will be used to investigate how the gut bacteria may be linked to better or worse responses to the rotavirus vaccine.
The aim of this project is to design a novel vaccine for Pneumococcal Meningitis and Sepsis. The project will assess the efficacy and safety of the vaccine using clinically relevant in vivo models. Novel adjuvanted formulations will be combined with newly discovered pneumococcal antigens and evaluated for their broad and cross-stereotype cellular immune protection.
Institute of Infection and Global Health, University of Liverpool
8 West Derby Street, Liverpool L69 7BE , United Kingdom
+44 (0)151 795 9626